From the bedside to the lab by Amberger-Murphy, Verena
THE NICB (National Institute for Cellular
Biotechnology) – located on Dublin City
University campus – has a long track record
of cancer research and is one of the leading
institutes in Ireland for translational cancer
research.
While research has been focused mainly on
non-neuronal cancers – for example,
breast, lung and more recently pancreas
and skin – tumours arising in the central
nervous system, in particular in the brain,
have not been studied at the NICB until
recently.
Malignant brain tumours are one of the
most virulent forms of cancer. They can
result in serious physical and cognitive
impairments. Brain tumours are often
described as cancer of the soul, since the
brain is the centre of thought, personality
and emotion. Brain tumours are cate-
gorised into primary and secondary.
Primary brain tumours originate in the
brain and rarely spread outside the brain,
whereas secondary tumours start outside
the brain, for example in the lung, breast or
skin, and metastasize to the brain.
Primary brain tumours
Primary brain tumours develop from
brain cells and give rise to gliomas, menin-
giomas, central nervous system
lymphomas, medulloblastomas, and
tumours of the nerve sheet.
The majority, however, arise from glial
cells, hence their name gliomas and
account for 42% of all primary brain
tumours and 71% of all malignant types.
Gliomas include oligodendrogliomas,
ependymomas, and astrocytomas/glioblas-
tomas, the latter representing the biggest
group (about 80%). Astrocytomas are
grouped according to their grade of malig-
nancy:
l Pilocytic astrocytoma (grade I), which is
mainly found in children
l Astrocytoma grade II, III
l Glioblastoma (grade IV) – which is most
common in adults between the age of 30
and 70.
There are no socio-economic boundaries
for the development of a these tumours.
Cause still unknown
The cause of primary brain tumours is
still unknown. Exposure to ionising radia-
tion and head injuries may be risk factors,
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as well as some inherited conditions for
example neurofibromatosis, Von Hippel-
Lindau syndrome, Li-Fraumeni syndrome,
and Turcot’s syndrome. However, only
about 5% of all cases can be attributed to
these causes.
In Ireland the incidence of primary brain
tumours is 7/100,000 people per year
(6.4/100.000 per year in the US).
There are about 316 new cases of primary
brain tumours diagnosed every year in the
Republic of Ireland and the mortality is
around 67%. Despite major improvements
in the surgical treatment the prognosis is
poor.
Survival depends on the tumour grade
and age. The five-year survival can be 65%
for grade I and II and less than 10% for
grade III and IV (glioblastoma) (Cancer Atlas
of the UK and Ireland 1991-2000).
The survival rate has improved very little
in the recent decade. The median survival
of glioblastoma (grade IV) is 189 days and
has not significantly changed within a 12-
year period (1993-2004).1
Treatment options for patients with
malignant glioma were limited and used
according to the principle ‘one size fits all’;
hence all subtypes were treated in the
same way.
Treatment included a surgical attempt to
remove visible tumour or at least reduce
the tumour size (removal of as much visible
tumour as possible) and radiotherapy,
whereas chemotherapy consisting of a
combination of procarbazine, vincristine,
and CCNU (PCV) played a marginal role. In
particular, glioblastoma (grade IV) was con-
sidered as highly chemoresistant.
Due to the infiltrative nature of these
lesions, recurrence is inevitable, even fol-
lowing an apparently complete surgical
removal as checked by post-operative MRI
or CT scan.
Sub-groups show more sensitivity
Many clinical trials using older or newer
drugs show that there are often a small
number of responders; whereas the major-
ity of patients enrolled would not respond,
which leads to the conclusion that the clin-
ical trial failed.
In 1988, however, Cairncross and McDon-
ald discovered that a subgroup of
malignant gliomas revealed a better sensi-
tivity to the combination chemotherapy
PCV. Investigating the tumour tissue they
found out that these tumours were charac-
terised by deletions at chromosomes 1p
and 19q2,3 and that patients bearing these
tumours would greatly benefit from the
treatment with PCV.
Another more recent finding came from
Stupp and his colleagues. They found that
the methylguanine methyltransferase
(MGMT) gene, which gives rise to a DNA
repair enzyme, is correlated with the
responsiveness to the newly developed
drug temozolomide (Temodar, Temodal).4,5
Patients, who expressed the methylated
form of the MGMT gene showed better
overall survival than patients with the non-
methylated form. The median survival was
22 months (versus 15 months) and the two-
year survival rate was 46% (versus 23%).
Tyrosine kinase inhibitors
In 2005, Mellinghoff et al published the
results of a clinical trial using the tyrosine
kinase inhibitors erlotinib (Tarceva) and
gefitinib (Iressa) in the treatment of malig-
nant glioma. They reported 20%
responders within the patient cohort, who
showed a reduction in tumour size mea-
sured by MRI.6
Responsiveness to these tyrosine kinase
inhibitors was associated with co-expres-
sion of EGFRvIII, a mutant variant of
epidermal growth factor receptor (EGFR),
and phosphatase and tensin homologue
(PTEN), a tumour suppressor, which is often
deleted in malignant gliomas. However,
others have shown that responsiveness to
EGFR blockade occurs independently of the
presence of mutated EGFRvIII.7
The results of a small number of respon-
ders reflect the cellular and molecular
heterogeneity of malignant gliomas. There
is a need for further in vitro studies on
patient tissue to be able to predict respon-
siveness to these types of targeted
therapies.
Irish Cancer Society funding
In 2006, we were able to secure funding
from the Irish Cancer Society for a three-
year translational research project, which is
performed in collaboration with the Neu-
ropathology Department in Beaumont
Hospital.
Together with consultant neuropatholo-
gist Michael Farrell we are trying to find a
molecular profile, which is predictive for in
vitro responsiveness to the EGFR inhibitors
erlotinib (Tarceva), gefitinib (Iressa), and
the platelet-derived growth factor receptor
(PDGFR) inhibitor imatinib (Gleevec).
EGFR and PDGFR and their downstream
effectors, for example Ras, Akt, and mTOR
(mammalian target of rapamycin) are criti-
cally involved in the regulation of glioma
survival, proliferation, invasion, and angio-
genesis.
EGFR and PDGFR are attractive targets,
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From our collection of results we hope to be able to find a
specific expression profile, which can be attributed to
responsiveness to tyrosine kinase inhibition and can be
used as predictors for individual treatment plans
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because they are
frequently
amplified
and/or over-
expressed in
malignant
gliomas.
Amplification
of EGFR is often
associated with
the expression
of a mutated
variant
EGFRvIII, which
is constitutively
active and
growth factor
independent.
The expression
of EGFRvIII is
linked to
increased
expression of
metallopro-
teinases and
extra cellular
matrix mole-
cules, which
results in
increased inva-
siveness of the
tumour.
Recent clinical
trials with
erlotinib and gefitinib have shown that
there is a large variability in patient
response. It became obvious that there was
a subset of patients who responded much
better to these inhibitors, however, the
cause for this variability is not yet fully
understood.
As yet there is very little data available on
the in-vitro effects of EGFR and PDGFR/c-kit
blockade on proliferation, invasion and
expression of proangiogenic factors in
glioma cells.
In vitro responsiveness
With our project we go from bed-side
(patient) back to the lab by investigating
patient tissue prior to any treatment
except resection. We determine in vitro
responsiveness to tyrosine kinase
inhibitors by measuring their effects on
proliferation, invasion and angiogenesis
signalling, which represent the three cardi-
nal biological characteristics of malignant
gliomas. Ethical approval for this study was
gained from Beaumont Hospital Ethics
Board in 2005.
Candidate patients are identified on the
basis of clinical presentation and imaging.
With the help of a patient information
leaflet the project is explained to these
patients by a senior house officer of the
Neuropathology Department and inter-
ested patients sign a written consent form
prior to surgery. Patients, who have
received tumour treatment before, are not
considered for this study, except cases
where tissue from the first intervention
was already included in the study.
During operation, fresh tumour tissue is
sent to the Neuropathology Department
for intra-operative diagnosis. Having
ensured that sufficient tissue has been har-
vested to allow for a definitive diagnosis,
residual tumour will be split with 50% of
the tissue snap frozen in liquid nitrogen
and the other half placed into cold salt
solution and transferred to the NICB labo-
ratory.
Beaumont Hospital and NICB
This project is a two arm study. At Beau-
mont Hospital, Rachel Howley, a PhD
student from the Royal College of Sur-
geons, performs immunohistochemical
and molecular analyses on formalin fixed
and on fresh frozen tissue, respectively.
Antibody staining provides information
about the expression status of EGFR,
EGFRvIII, PDGFRα and β, PTEN, and a
number of down-stream molecules within
the signalling pathways.
Molecular analysis of genomic tissue
DNA includes DNA sequencing, FISH (fluo-
rescence in situ hybridisation), and real
time PCR (polymerase chain reaction) pro-
ducing information about gene expression
levels of EGFR, EGFRvIII, PDGFR, and PTEN.
At the NICB, Paula Kinsella, a PhD student
at the NICB, and I develop primary cell lines
from the tissue samples. These cell lines are
tested for their proliferative and invasive
activity as well as for their sensitivity to the
tyrosine kinase inhibitors erlotinib, gefi-
tinib, and imatinib and to temozolomide
(the chemotherapy drug currently used in
the treatment of gliomas) and docetacel
(Taxotere), a powerful chemotherapy drug
used for a variety of other cancer types.
Using Western Blotting technique we
determine protein expression of EGFR,
EGFRvIII, PDGFR, and the same down-
stream molecules, which are analysed in
the tissue samples in Beaumont.
DCU grant
With an additional grant, secured in early
2007 from DCU’s Faculty of Science and
Health, we will analyse expression of
microRNAs, which are small regulatory RNA
fragments, in two groups of our primary
tumour cell lines chosen according to their
proliferative activity.
MicroRNAs have been identified to play a
critical role in developmental and physio-
logical processes and are implicated in the
pathogenesis of cancer.
They represent small non-coding RNA
molecules which can either act as onco-
genes or as suppressor genes. In particular,
miRNA-21 has been found to be involved in
inhibiting apoptosis through PI3-kinase
activation, which is dependent on the dele-
tion of phosphatase and tensin homolog
(PTEN) from chromosome 10.
Using low density arrays we will deter-
mine differences in microRNA expression
between fast and low proliferating cell
lines and functionally validate identified
candidates in each cell line. This analysis
adds another dimension to our transla-
tional study.
Results from both arms and the
microRNA study are collected in a database
and are compared to maximise the validity
of in vitro glioma response data. The data-
base also includes key clinical, radiologic,
pathologic and – if available- follow-up
information of each patient, which can be
included into the analysis of the data.
Specific expression profile
From this collection of results we hope to
be able to find a specific expression profile,
which can be attributed to responsiveness
to tyrosine kinase inhibition and can be
used as predictors for individual treatment
plans.
A secondary but important long-term
goal is the development of reverse phase
microarrays, which represents a rapid, high
throughput technique for the characterisa-
tion of signalling pathways in human
gliomas, which would allow a more accu-
rate diagnosis and a personalised
treatment plan.
Verena Amberger-Murphy is senior
research scientist at the National Institute
for Cellular Biotechnology (NICB), Dublin
City University
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